Bristol-Myers Squibb: Difference between revisions

Jump to navigation Jump to search
(New page: {{Infobox_Company | | company_name = Bristol-Myers Squibb Company | company_logo = Image:Bms.gif | company_type = Public({{nyse|BMY}}) | company_slogan = ...)
 
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Line 15: Line 15:
}}
}}
{{SI}}
{{SI}}
{{EH}}
 


[[Image:Bristolmyersprincetonfacility.jpg|thumb|left|250px|A Bristol-Myers Squibb research campus in [[Lawrenceville, New Jersey]]]]
[[Image:Bristolmyersprincetonfacility.jpg|thumb|left|250px|A Bristol-Myers Squibb research campus in [[Lawrenceville, New Jersey]]]]
Line 97: Line 97:
[[Category:Companies established in 1887]]
[[Category:Companies established in 1887]]
[[Category:Dental companies]]
[[Category:Dental companies]]
{{SIB}}
 
[[de:Bristol-Myers Squibb]]
[[de:Bristol-Myers Squibb]]
[[fr:Bristol-Myers-Squibb]]
[[fr:Bristol-Myers-Squibb]]

Revision as of 23:10, 8 August 2012

Template:Infobox Company

WikiDoc Resources for Bristol-Myers Squibb

Articles

Most recent articles on Bristol-Myers Squibb

Most cited articles on Bristol-Myers Squibb

Review articles on Bristol-Myers Squibb

Articles on Bristol-Myers Squibb in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bristol-Myers Squibb

Images of Bristol-Myers Squibb

Photos of Bristol-Myers Squibb

Podcasts & MP3s on Bristol-Myers Squibb

Videos on Bristol-Myers Squibb

Evidence Based Medicine

Cochrane Collaboration on Bristol-Myers Squibb

Bandolier on Bristol-Myers Squibb

TRIP on Bristol-Myers Squibb

Clinical Trials

Ongoing Trials on Bristol-Myers Squibb at Clinical Trials.gov

Trial results on Bristol-Myers Squibb

Clinical Trials on Bristol-Myers Squibb at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bristol-Myers Squibb

NICE Guidance on Bristol-Myers Squibb

NHS PRODIGY Guidance

FDA on Bristol-Myers Squibb

CDC on Bristol-Myers Squibb

Books

Books on Bristol-Myers Squibb

News

Bristol-Myers Squibb in the news

Be alerted to news on Bristol-Myers Squibb

News trends on Bristol-Myers Squibb

Commentary

Blogs on Bristol-Myers Squibb

Definitions

Definitions of Bristol-Myers Squibb

Patient Resources / Community

Patient resources on Bristol-Myers Squibb

Discussion groups on Bristol-Myers Squibb

Patient Handouts on Bristol-Myers Squibb

Directions to Hospitals Treating Bristol-Myers Squibb

Risk calculators and risk factors for Bristol-Myers Squibb

Healthcare Provider Resources

Symptoms of Bristol-Myers Squibb

Causes & Risk Factors for Bristol-Myers Squibb

Diagnostic studies for Bristol-Myers Squibb

Treatment of Bristol-Myers Squibb

Continuing Medical Education (CME)

CME Programs on Bristol-Myers Squibb

International

Bristol-Myers Squibb en Espanol

Bristol-Myers Squibb en Francais

Business

Bristol-Myers Squibb in the Marketplace

Patents on Bristol-Myers Squibb

Experimental / Informatics

List of terms related to Bristol-Myers Squibb


File:Bristolmyersprincetonfacility.jpg
A Bristol-Myers Squibb research campus in Lawrenceville, New Jersey

Bristol-Myers Squibb (Template:Nyse), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were graduates of Hamilton College), and E.R. Squibb Corporation. The New York City-based company's Chairman and CEO was most recently Peter R. Dolan. Dolan was fired in September 2006 for his handling of a patent dispute over the drug Plavix, and was replaced with interim CEO James Cornelius. Since that time, Cornelius had assumed the permanent role of CEO and Chairman upon the retirement of James Robinson, III. Robinson was appointed Chairman as part of the settlement regarding the "channel-stuffing" scandal (see Scandals and allegations). The company was crippled by a series of scandals through the 2000s which included "channel-stuffing" and resulted in $1B+ in state and federal fines. As part of a deal to avoid federal prosecution Bristol was placed under the oversight of a Federal judge and ex-FBI director, Louis Freeh, was placed on the BOD for a 2 year period. In addition, the disgraced head of the Pharma group, Richard Lane, and the ex-CFO, Fred Schiff, were indicted for federal securities violations. BMS' primary R&D sites are located in Lawrenceville, New Jersey (formerly Squibb) and Wallingford, Connecticut (formerly Bristol-Myers), with other sites around the US, in Ireland and in other countries. Cornelius has embarked on mission of selling the company. In the interim a major restructuring has been implemented which involves focusing on biologic products along with cost-cutting through a 3-year 20+% headcount reduction involving primarily layoffs of employees, and the outsourcing and off-shoring of operations. A significant move will be made to replace US R&D with inexpensive operations in India and China.

In 2005, BMS was among 53 entities that contributed the maximum of $250,000 to the second inauguration of President George W. Bush.[1] [2] [3]

BMS is a Fortune 500 Company (#129 in 2007 list).

Bristol-Myers Squibb manufactures prescription pharmaceuticals and health care products in several therapeutic areas. It is also the parent company of Mead Johnson which manufactures nutritional products such as Enfamil baby formulas and infant vitamin supplements like Tri-Vi-Sol and ConvaTec, a world leader in ostomy and wound care products. Bristol-Myers Squibb has a mission to "Extend and Enhance Human Life" and works to provide help for areas of unmet medical need.

Spokesman

Lance Armstrong has appeared in several of the company's marketing campaigns, as a survivor of testicular cancer that was treated with BMS medication.

Pharmaceuticals

The following is a list of key pharmaceutical products:[4]

Taxol

File:Squibb Chocolate Vitavose Milk Supplement advertisement, 1932.jpg
1932 advertisement for Squibb Chocolate Vitavose Milk Supplement from E. R. Squibb & Sons, one of the ancestor companies of Bristol-Myers Squibb.

At one time, BMS held the solitary contract to harvest the bark of endangered yew trees on United States territory for the manufacture of chemotherapy drug paclitaxel (Taxol). Current paclitaxel production comes from renewable sources. BMS also held the original paclitaxel license, but there are now multiple generic producers.

Products under development

The following is a list of products under development:[5]

Scandals and allegations

On June 30th, 1999, consumer advocate Ralph Nader testified before the House Budget Committee on corporate welfare. Nader pointed out that taxol was developed in large part by the federal government while Bristol-Myers Squibb maintained production rights, with potential earnings of over $1 billion per year.[6]

The company was involved in an accounting scandal[1] in 2002 that resulted in a significant restatement of revenues from 1999–2001. The restatement was the result of an improper booking of sales related to "channel stuffing," or the practice of offering excess inventory to customers in order to reflect higher sales numbers. The company has since settled with the United States Department of Justice and Securities and Exchange Commission, agreeing to pay $150 million while neither admitting nor denying guilt.[7]

According to an FTC consent order filed in 2003,[8] the company

engaged in a series of anticompetitive acts over the past decade to obstruct the entry of low-price generic competition for three of Bristol's widely-used pharmaceutical products: two anti-cancer drugs, Taxol and Platinol, and the anti-anxiety agent BuSpar. [...] Bristol avoided competition by abusing federal regulations in order to block generic entry; deceived the U.S. Patent and Trademark Office (PTO) to obtain unwarranted patent protection; paid a would-be generic rival over $70 million not to bring any competing products to market; and filed baseless patent infringement lawsuits to deter entry by generics.

The company has also been sued in this matter by state attorneys general to recover monetary damages.

A criminal investigation of the company was made public in July 2006, and the FBI raided the company's corporate offices. The investigation centered around the distribution of Plavix and charges of collusion.[9]

On September 12, 2006, a federal monitor, former Federal Judge Frederick B. Lacey, urged the company to remove then CEO Peter Dolan over the Plavix dispute. Later that day, BMS announced that Dolan would indeed step down.[10].

Under Cornelius's reign, all executives involved in the "channel-stuffing" and generic competition scandals have since left the company. The latest being Andrew Bodner, Executive VP, who has been indicted due to his involvement in the Plavix-Apotex episode.

References

  1. Drinkard, Jim (2005-01-17). "Donors get good seats, great access this week". USA Today. Retrieved 2008-05-25.
  2. "Financing the inauguration". USA Today. Retrieved 2008-05-25.
  3. "Some question inaugural's multi-million price tag". USA Today. 2005-01-14. Retrieved 2008-05-25.
  4. http://www.bms.com/aboutbms/data/
  5. http://www.bms.com/research/content/data/pipeline.html
  6. http://www.nader.org/index.php?/archives/307-Corporate-Welfare-Horror-Stories.html
  7. SEC News Digest, August 9, 2004.
  8. News Release about Consent Order against Bristol-Myers, March 7, 2003
  9. Business Report, July 31, 2006. Accessed September 7, 2006
  10. CNN.com, September 12, 2006. Accessed September 12, 2006

See also

External links

de:Bristol-Myers Squibb id:Bristol-Myers Squibb it:Bristol-Myers Squibb sv:Bristol-Myers Squibb

Template:WH Template:WS